BM
BMRA.US Biomerica Inc
- Market cap
- USD 6.25M
- P/E
- -
- P/B
- 1.64x
- ROE
- -135.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is BMRA.US undervalued?
Graham numberThe Graham number of Biomerica Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biomerica Inc fundamental analysis
No fundamental analysis for Biomerica Inc yet.
Biomerica Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biomerica Inc
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical condi…
Full company profileBiomerica Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biomerica Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.79M | 5.56M | 5.20M | 6.69M | 7.20M | 18.9M | 5.34M | 5.42M | 5.31M | 4.45M | 5.06M |
| Gross Profit | 2.02M | 1.75M | 1.29M | 1.78M | 366K | 2.98M | 446K | 611K | 498K | 362K | 412K |
| Operating Income | -955K | -1.48M | -2.41M | -2.40M | -7.50M | -4.53M | -7.22M | -6.37M | -5.14M | -5.32M | -4.91M |
| EBITDA | -689K | -1.25M | -2.21M | -1.93M | -7.06M | -3.94M | -6.74M | -5.56M | -4.57M | -4.90M | -4.84M |
| Net Income | -909K | -1.47M | -2.39M | -2.34M | -7.45M | -4.53M | -7.14M | -5.98M | -4.97M | -3.78M | -4.93M |
| EPS | -0.11 | -0.17 | -0.26 | -0.23 | -0.62 | -0.36 | -0.50 | -0.36 | -2.16 | -1.30 | -1.50 |
| Balance Sheet | |||||||||||
| Total Assets | 5.02M | 5.22M | 5.25M | 17.3M | 11.8M | 11.4M | 14.5M | 9.25M | 5.95M | 6.76M | 8.07M |
| Total Liabilities | 529K | 897K | 1.26M | 3.05M | 2.59M | 3.05M | 2.73M | 2.66M | 1.84M | 4.13M | 4.42M |
| Shareholders' Equity | 4.49M | 4.33M | 3.98M | 14.2M | 9.23M | 8.32M | 11.7M | 6.59M | 4.11M | 2.63M | 3.65M |
| Cash & Short-term Investments | 1.23M | 1.20M | 687K | 8.64M | 4.20M | 5.92M | 9.72M | 4.17M | 2.40M | 1.31M | 2.73M |
| Total Debt | - | - | - | 1.78M | 1.62M | 1.38M | 1.08M | 785K | 458K | 2.38M | 2.33M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -723K | -1.17M | -2.24M | -4.30M | -5.25M | -481K | -5.47M | -5.36M | -3.84M | -3.42M | -3.21M |
| Capital Expenditure | 96.1K | 130K | 171K | 119K | 296K | 170K | 78.0K | 115K | 37.0K | 1.00K | 0.00 |
| Free Cash Flow | -819K | -1.30M | -2.42M | -4.42M | -5.55M | -651K | -5.55M | -5.48M | -3.88M | -3.42M | -3.21M |
| Ratios | |||||||||||
| ROE | -20.2% | -33.9% | -60.1% | -16.5% | -80.7% | -54.4% | -60.9% | -90.7% | -121.1% | -143.5% | -135.1% |
| ROA | -18.1% | -28.1% | -45.6% | -13.6% | -63.0% | -39.8% | -49.4% | -64.6% | -83.7% | -55.9% | -61.1% |
| Net Profit Margin | -15.7% | -26.3% | -46.0% | -34.9% | -103.4% | -24.0% | -133.7% | -110.4% | -93.6% | -84.8% | -97.4% |
| Debt to Equity | - | - | - | 0.13x | 0.18x | 0.17x | 0.09x | 0.12x | 0.11x | 0.91x | 0.64x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biomerica Inc dividends
Biomerica Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Apr 21, 2025.
Who owns Biomerica Inc
- Insiders 21.92%
- Institutions 3.02%
- Public & others 75.06%
- Shares outstanding 4.60M
- Free float 4.22M
Top funds holding BMRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 12.6K | 0.27% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 3.49K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.72K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding BMRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 26.4K | 0.57% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 24.3K | 0.53% | -56.56% | Jun 2026 |
| BlackRock Inc | 18.6K | 0.41% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 14.5K | 0.32% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 12.6K | 0.27% | 0.00% | Jun 2026 |
| LPL Financial Corp | 10.8K | 0.24% | 0.00% | Jun 2026 |
| UBS Group AG | 6.95K | 0.15% | +1,239.31% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 6.61K | 0.14% | 0.00% | Jun 2026 |
| Goss Wealth Management LLC | 3.60K | 0.08% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 238.00 | 0.01% | 0.00% | Jun 2026 |
| Hollencrest Securities, LLC | 200.00 | 0.00% | -75.76% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 125.00 | 0.00% | 0.00% | Jun 2026 |
| FMR Inc | 83.00 | 0.00% | 0.00% | Jun 2026 |
| IFG Advisory, LLC | 25.00 | 0.00% | 0.00% | Jun 2026 |
| Larson Financial Group, LLC | 12.00 | 0.00% | 0.00% | Jun 2026 |
| Mcf Advisors, LLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
Biomerica Inc company profile
- Company name
- Biomerica Inc
- Ticker
- BMRA.US
- Exchange
- USA Stocks
- Listed since
- Jan 3, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 50
- Fiscal year end
- May
- Address
- 17571 Von Karman Avenue, Irvine, CA, United States, 92614
- Phone
- 949 645 2111
- Website
- biomerica.com
About Biomerica Inc
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Biomerica Inc management
5- Mr. Zackary S. IraniCEO & Director · born 1966
- Mr. Allen C. BarbieriExecutive Vice-Chairman of the Board & Corporate Secretary · born 1958
- Ms. Xiaoxuan QuPrincipal Financial Officer & Principal Accounting Officer · born 1993
- Ms. Lucy Liu Ph.D.Director of Manufacturing & Technical Operations
- Mr. Scott MadelChief Commercial Officer